Franklin Biolabs Names its First CEO
Franklin Biolabs, a Penn spinout founded by James Wilson, MD, PhD, Rose H. Weiss Professor in Penn Medicine, has named Vatsala Naageshwaran as its first chief executive officer.
Ocuphire Pharma Announces Acquisition of Opus Genetics, a Penn startup based on technology developed by Dr. Jean Bennett and colleagues
The merger between Opus and Ocuphire creates a transformative biotech company, renamed Opus Genetics, Inc, which is committed to the development of gene therapies for the treatment of IRDs.
EpiVario Secures Key Patents for Innovative Addiction Treatment
EpiVario, Inc., a Penn spinout co-founded by Shelley Berger, PhD, the Daniel S. Och University Professor at Penn Medicine, announced the issuance to Penn of US Patent No. 12,077,527.
Penn spinout REGENXBIO Presents Positive Data from Phase II Study for Wet AMD Treatment
Penn spinout REGENXBIO, co-founded by James Wilson, MD, PhD, Rose H. Weiss Professor in Penn Medicine, announced positive results from a phase II study for its treatment ABBV-RGX-314.
Interius BioTherapeutics Doses First Patient within vivo CAR T cell therapy
Interius has dosed its first patient in a clinical trial of its lead drug candidate, INT2104, an in vivoCAR T cell therapy that targets B-cell malignancies
Penn Spinout ViTToria Biotherapeutics Raises $25M
This funding is a $10 million extension to its previous $15 million financing secured in November 2023.
NIH Awards $6.9 Million to a Team of Scientists at Penn and UC San Diego to Advance Potential Alzheimer’s Disease Treatment
The team discovered that a new compound, CNDR-51997, was effective in restoring brain health in mouse models of Alzheimer's disease.
Penn Leads NSF Sponsored AIRFoundry to Revolutionize RNA Research, Leveraging AI to Further Optimize and Innovate
It is an $18-million initiative focused on advancing RNA research through AI-driven innovation and advanced manufacturing techniques.
Penn spinout Linnaeus Therapeutics secures an additional $1.6M in Funding
Penn spinout Linnaeus Therapeutics has raised another $1.6 million in financing, bringing its cumulative funding total to over $13 million since 2018.
iECURE included on list of Fierce Biotech’s 2024 Fierce 15
iECURE was recognized for its innovative approach to treating rare childhood diseases by developing therapies that correct gene function directly inside the body.